Skip to content
Peter Attia MDPeter Attia MD

253 ‒ Hormone replacement therapy and the Women’s Health Initiative: re-examining the results

Watch the full episode and view show notes here: https://bit.ly/3HJxWwn Become a member to receive exclusive content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ JoAnn Manson is a world-renowned endocrinologist, epidemiologist, and Principal Investigator for the Women’s Health Initiative (WHI). In this episode, she dives deep into the WHI to explain the study design, primary outcome, confounding factors, and nuanced benefits and risks of hormone replacement therapy (HRT). JoAnn reflects on how a misinterpretation of the results, combined with sensationalized headlines regarding an elevated risk of breast cancer, led to a significant shift in the perception and utilization of HRT. From there, they take a closer look at the breast cancer data to separate fact from fiction. Additionally, JoAnn gives her take on how one should weigh the risks and benefits of HRT and concludes with a discussion on how physicians can move towards better HRT practices. We discuss: Intro [0:00] The Women’s Health Initiative: the original goal of the study, hormone formulations used, and potential confounders [4:15]; Study design of the Women’s Health Initiative, primary outcome, and more [16:00]; JoAnn’s personal hypothesis about the ability of hormone replacement therapy to reduce heart disease risk prior to the WHI [26:45]; The relationship between estrogen and breast cancer [30:45]; Why the WHI study was stopped early, and the dramatic change in the perception and use of HRT due to the alleged increase in breast cancer risk [37:30]; What Peter finds most troubling about the mainstream view of HRT and a more nuanced look at the benefits and risks of HRT [45:15]; HRT and bone health [56:00]; The importance of timing when it comes to HRT, the best use cases, and advice on finding a clinician [59:30]; A discussion on the potential impact of HRT on mortality and a thought experiment on a long-duration use of HRT [1:03:15]; Moving toward better HRT practices, and the need for more studies [1:10:00]; and More. -------- About: The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 60 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more. Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. Learn more: https://peterattiamd.com Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies.

Peter AttiahostJoAnn Mansonguest
May 8, 20231h 20mWatch on YouTube ↗

At a glance

WHAT IT’S REALLY ABOUT

Dr. JoAnn Manson Re-examines Women's Health Initiative Findings on Hormone Therapy

  1. The WHI was launched in the early 1990s to test in randomized trials whether hormone therapy prevents heart disease and other chronic conditions, after observational studies suggested benefit that Manson suspected was partly confounded.
  2. Participants averaged 63 years old and were often more than a decade past menopause, and the estrogen-plus-progestin arm was stopped early after 5.6 years because of increased breast cancer, no heart disease reduction, and an unfavorable overall risk-benefit index.
  3. Attia and Manson agree the breast cancer increase with estrogen plus MPA was small in absolute terms (about one extra case per thousand women per year), and that estrogen alone did not raise breast cancer risk, but Manson cautions that estrogen's role in breast cancer is supported by other evidence and results may not generalize across formulations.
  4. Manson says the results were wrongly extrapolated to women in their 40s and 50s with bothersome hot flashes, who were denied treatment, while stopping hormone therapy for chronic disease prevention in older women was appropriate.
  5. Manson stresses individualized shared decision-making, favors transdermal estradiol and micronized progesterone, and says another WHI-scale trial is unlikely, while Attia argues long-term use for bone protection could outweigh risks but acknowledges that this can't be tested.

IDEAS WORTH REMEMBERING

5 ideas

The WHI tested prevention of chronic disease, not treatment of menopausal symptoms.

Manson explains that the trial addressed whether hormones prevent heart disease and cognitive decline, a different question from relieving hot flashes, for which hormone therapy is FDA approved.

The trial population was older than typical symptomatic women.

The average age was 63, and enrollment was by age 50 to 79 rather than time since menopause, so many women were well past early menopause when they began therapy.

The breast cancer signal was small in absolute terms and tied to the progestin combination.

Estrogen plus MPA showed roughly one extra case per thousand women per year, while estrogen alone showed no increase and later a reduction. Manson agrees MPA is likely responsible but says estrogen's role in breast cancer cannot be dismissed.

Results were over-extrapolated to younger women with symptoms.

Manson says use fell 70 to 80 percent after the findings, which was positive for prevention uses but wrongly denied treatment to healthy women in early menopause with distressing symptoms.

Timing matters for risks and benefits.

Absolute risks were lower in women in their 50s, with signals of lower heart disease and about 30 percent lower mortality that were not statistically significant, while estrogen alone in women 70 to 79 showed a possible mortality increase.

WORDS WORTH SAVING

5 quotes

It's amazing how the pendulum has swung. So in the 1980s, 1990s, the perception was that hormone therapy was good for all women. Then after the WHI in the early 2000s, the pendulum was in the opposite direction, that hormone therapy is bad for all women.

— JoAnn Manson

Women never should have been denied hormone therapy for the treatment of bothersome, distressing hot flashes, night sweats to improve their quality of life, especially generally healthy women in early menopause who have such low absolute rates of adverse events.

— JoAnn Manson

In many ways, timing is everything when it comes to hormone therapy because not only are the absolute risks, the risk of having adverse events on hormone therapy lower in the younger women, women in early menopause

— JoAnn Manson

The problem was it was overextrapolated. The results were extrapolated to women in early menopause taking hormone therapy for the hot flashes, night sweats.

— JoAnn Manson

I think there's a lost generation of women. I think there's 20 years of women who entered menopause who were denied HRT due to the ignorance of their physicians and the irresponsibility of the media.

— Peter Attia

Women's Health Initiative design and eligibilityObservational studies versus randomized trialsEstrogen plus progestin versus estrogen aloneBreast cancer relative versus absolute riskTiming of hormone therapy and age of initiationHip fracture and bone health debateFinding a menopause-trained clinician and non-hormonal options

High quality AI-generated summary created from speaker-labeled transcript.

Get more out of YouTube videos.

Read along on your phone, search it beside the video, or ask your favorite AI app what was said.

iOSAndroidClaudeChromeChatGPTComing soon